Merck (MRK) Highlights Long-Term Survival Benefit in KEYTRUDA® (pembrolizumab)
Tweet Send to a Friend
Merck (NYSE: MRK) today announced long-term efficacy data from the Phase 3 KEYNOTE-006 study and the melanoma cohort of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
